🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 28

  1. 1 mg/kg GR-MD-02

    GALECTIN THERAPEUTICS INC

    Metastatic Melanoma

    phase 1 mab completed

    1 trial

  2. 145 mg/m2 NKTR 102

    Nektar Therapeutics UK Limited

    Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  3. 177Lu-DOTA-TLX591

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 mab completed

    1 trial

  4. 177Lu-TLX250 and Peposertib

    Telix Innovations

    Solid Tumor, Adult

    phase 1 other active

    1 trial

  5. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  6. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  7. 18F-PEG6-IPQA

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 1 small molecule completed

    1 trial

  8. 19(T2)28z1xx CAR T cells

    Takeda

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule active

    1 trial

  9. 19(T2)28z1xx TRAC T cell

    Takeda

    B-Cell Lymphoma

    phase 1 mab active

    1 trial

  10. 20 mg/kg TRU-016 + Rituximab

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  11. 2X-121 and dovitinib

    Allarity Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule on hold

    1 trial

  12. 2mg INO-5150 and electroporation device CELLECTRA®-5P

    INOVIO PHARMACEUTICALS, INC.

    Prostate Cancer

    phase 1 mab completed

    1 trial

  13. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 1 other active

    1 trial

  14. 609A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Solid Tumors

    phase 1 small molecule active

    2 trials

  15. 64Cu-DOTA-TLX592

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 small molecule completed

    1 trial

  16. 68-Ga PSMA11

    Telix Innovations

    Prostate Adenocarcinoma

    phase 1 small molecule active

    1 trial

  17. 68Ga-AAZTA-NI-093

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 1 small molecule active

    1 trial

  18. 68Ga-BNU-PSMA

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 other active

    1 trial

  19. 68Ga-DOTA/NOTA-FAPI-04

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  20. 68Ga-FAPI-Biotin

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  21. 68Ga-JH04

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  22. 68Ga-JH12

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  23. 68Ga-MGS5

    The First People's Hospital of Lianyungang

    Medullary Thyroid Carcinoma

    phase 1 small molecule active

    1 trial

  24. 68Ga-NNS309

    Novartis Pharmaceuticals

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  25. 68Ga-NODAGA-SNA006

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 mab completed

    1 trial

  26. 68Ga-PSMA-11

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  27. 68Ga-Pentixafor

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 1 small molecule active

    1 trial

  28. 89Zr-DFO-YS5

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  29. 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

    Telix Innovations

    Soft Tissue Sarcoma

    phase 1 small molecule active

    1 trial

  30. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Carcinoma

    phase 1 other completed

    1 trial

  31. 89Zr-Girentuximab

    Telix Innovations

    Urothelial Carcinoma

    phase 1 small molecule completed

    1 trial

  32. 89Zr-girentuximab

    Telix Innovations

    Carcinoma, Renal Cell

    phase 1 other completed

    1 trial

  33. 89Zr˗DFO˗REGN5054

    Regeneron UK Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  34. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Refractory Cancer

    phase 1 small molecule terminated

    1 trial

  35. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial

  36. A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  37. A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

    Celltrion Healthcare Australia Pty Ltd

    Completely Resected Stage IIB, IIC, and III Melanoma

    phase 1 other active

    1 trial

  38. A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  39. A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

    KYOWA KIRIN AUSTRALIA PTY LTD

    T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)

    phase 1 other active

    1 trial

  40. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  41. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  42. A First-in-Human Study to Test the Safety and Effects of the Investigational Drug IPH4502 in People with Advanced Cancers

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  43. A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  44. A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product

    Century Therapeutics

    Hematological or solid tumor malignancies or autoimmune diseases

    phase 1 other active

    1 trial

  45. A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 1 other active

    1 trial

  46. A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  47. A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  48. A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

    Fondazione Telethon ETS

    High-Risk, Surgically Resectable Melanoma

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.